Cincinnati Business Courier: Queen City Angels-backed Alphyn eyes another fundraise amid ‘positive’ clinical study results
by Liz Engel
Alphyn Biologics, a clinical-stage dermatology company developing a new class of drugs for skin diseases, will pursue a Series B financing round in 2023.
CONTACTS
Corporate:
Neal Koller
nkoller@alphynbiologics.com
(410) 690-8687
Media:
Susan Thomas
susan@endpointcommunications.net
(619) 540-9195